{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:51:58Z","timestamp":1784307118937,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Autoreaktive B\u2011Zellen spielen eine Schl\u00fcsselrolle in der Pathogenese von Autoimmunerkrankungen, wie dem systemischen Lupus erythematodes (SLE). Daher kommt einer effizienten Depletion von B\u2011Zellen bei Autoimmunerkrankungen eine besondere Rolle zu, insbesondere dann, wenn es sich um schwere Verlaufsformen der Erkrankung handelt. Die Therapie mit chim\u00e4ren Antigenrezeptor(CAR)-T-Zellen, urspr\u00fcnglich f\u00fcr die Behandlung von B\u2011Zell-Lymphomen und Leuk\u00e4mien entwickelt, bietet die M\u00f6glichkeit, B\u2011Zellen auch in tieferen Geweben zu depletieren. Erste Ergebnisse von Fallserien mit diesem Verfahren bei SLE, Myositiden und systemischer Sklerose sind sehr positiv. Diese \u00dcbersichtsarbeit gibt einen \u00dcberblick \u00fcber Ablauf, Wirkmechanismus, bisherige Ergebnisse sowie die Forschungsagenda der CAR-T-Zell-Therapie bei Autoimmunerkrankungen.<\/jats:p>","DOI":"10.1007\/s00393-024-01514-x","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T06:02:31Z","timestamp":1716444151000},"page":"485-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR-T-Zell-Therapie in der Rheumatologie\u00a0\u2013 Was wissen wir bisher?","CAR T-cell therapy in rheumatology\u2014What we know so far?"],"prefix":"10.1007","volume":"83","author":[{"given":"Melanie","family":"Hagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wirsching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jule","family":"Taubmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mackensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Grieshaber-Bouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"10416","key":"1514_CR1","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett\u00a0G, Mackensen\u00a0A, Mougiakakos\u00a0D (2023) CAR T\u2011cell therapy in autoimmune diseases. Lancet 402(10416):2034\u20132044","journal-title":"Lancet"},{"issue":"4","key":"1514_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang\u00a0L, Wang\u00a0FS, Gershwin\u00a0ME (2015) Human autoimmune diseases: a\u00a0comprehensive update. J\u00a0Intern Med 278(4):369\u2013395","journal-title":"J Intern Med"},{"issue":"6","key":"1514_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos\u00a0GC (2020) Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 21(6):605\u2013614","journal-title":"Nat Immunol"},{"issue":"4","key":"1514_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000024","volume":"4","author":"MM Fernando","year":"2008","unstructured":"Fernando\u00a0MM, Stevens\u00a0CR, Walsh\u00a0EC, De Jager\u00a0PL, Goyette\u00a0P, Plenge\u00a0RM et\u00a0al (2008) Defining the role of the MHC in autoimmunity: a\u00a0review and pooled analysis. Plos Genet 4(4):e1000024","journal-title":"Plos Genet"},{"issue":"25","key":"1514_CR5","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards\u00a0JC, Szczepanski\u00a0L, Szechinski\u00a0J, Filipowicz-Sosnowska\u00a0A, Emery\u00a0P, Close\u00a0DR et\u00a0al (2004) Efficacy of B\u2011cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N\u00a0Engl J Med 350(25):2572\u20132581","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"1514_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard.2009.109041","volume":"69","author":"RM Thurlings","year":"2010","unstructured":"Thurlings\u00a0RM, Teng\u00a0O, Vos\u00a0K, Gerlag\u00a0DM, Aarden\u00a0L, Stapel\u00a0SO et\u00a0al (2010) Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69(2):409\u2013412","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1514_CR7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ajt.12220","volume":"13","author":"EG Kamburova","year":"2013","unstructured":"Kamburova\u00a0EG, Koenen\u00a0HJ, Borgman\u00a0KJ, ten Berge\u00a0IJ, Joosten\u00a0I, Hilbrands\u00a0LB (2013) A\u00a0single dose of rituximab does not deplete B\u00a0cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 13(6):1503\u20131511","journal-title":"Am J Transplant"},{"issue":"1","key":"1514_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill\u00a0JT, Neuwelt\u00a0CM, Wallace\u00a0DJ, Shanahan\u00a0JC, Latinis\u00a0KM, Oates\u00a0JC et\u00a0al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase\u00a0II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1514_CR9","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1002\/art.20592","volume":"50","author":"JH Anolik","year":"2004","unstructured":"Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I (2004) Rituximab improves peripheral B\u00a0cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50(11):3580\u20133590. https:\/\/doi.org\/10.1002\/art.20592","journal-title":"Arthritis Rheum"},{"key":"1514_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"1514_CR11","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMp1711886","volume":"377","author":"L Rosenbaum","year":"2017","unstructured":"Rosenbaum\u00a0L (2017) Tragedy, Perseverance, and Chance\u2014The Story of CAR\u2011T Therapy. N\u00a0Engl J Med 377(14):1313\u20131315","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"1514_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter\u00a0DL, Levine\u00a0BL, Kalos\u00a0M, Bagg\u00a0A, June\u00a0CH (2011) Chimeric antigen receptor-modified T\u00a0cells in chronic lymphoid leukemia. N\u00a0Engl J Med 365(8):725\u2013733","journal-title":"N Engl J Med"},{"issue":"6","key":"1514_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R et\u00a0al (2020) Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545\u2013553","journal-title":"N Engl J Med"},{"issue":"7","key":"1514_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong\u00a0EA, Ruella\u00a0M, Schuster\u00a0SJ (2021) Five-Year Outcomes for Refractory B\u2011Cell Lymphomas with CAR T\u2011Cell Therapy. N\u00a0Engl J Med 384(7):673\u2013674","journal-title":"N Engl J Med"},{"issue":"17","key":"1514_CR15","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","volume":"133","author":"SS Neelapu","year":"2019","unstructured":"Neelapu\u00a0SS (2019) CAR\u2011T efficacy: is conditioning the key? Blood 133(17):1799\u20131800","journal-title":"Blood"},{"issue":"482","key":"1514_CR16","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal\u00a0R, Richardson\u00a0N (2019) Sustained B\u00a0cell depletion by CD19-targeted CAR T\u00a0cells is a\u00a0highly effective treatment for murine lupus. Sci Transl Med 11(482):eaav1648. https:\/\/doi.org\/10.1126\/scitranslmed.aav1648","journal-title":"Sci Transl Med"},{"issue":"8","key":"1514_CR17","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin\u00a0X, Xu\u00a0Q, Pu\u00a0C, Zhu\u00a0K, Lu\u00a0C, Jiang\u00a0Y et\u00a0al (2021) Therapeutic efficacy of anti-CD19 CAR-T\u00a0cells in a\u00a0mouse model of systemic lupus erythematosus. Cell Mol Immunol 18(8):1896\u20131903","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"1514_CR18","first-page":"1954","volume":"73","author":"C Orvain","year":"2021","unstructured":"Orvain\u00a0C, Boulch\u00a0M, Bousso\u00a0P, Allanore\u00a0Y, Avouac\u00a0J (2021) Is There a\u00a0Place for Chimeric Antigen Receptor\u2011T Cells in the Treatment of Chronic Autoimmune. Ann Rheum Dis 73(11):1954\u20131965","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1514_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos\u00a0D, Kr\u00f6nke\u00a0G, V\u00f6lkl\u00a0S, Kretschmann\u00a0S, Aigner\u00a0M, Kharboutli\u00a0S et\u00a0al (2021) CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N\u00a0Engl J Med 385(6):567\u2013569","journal-title":"N Engl J Med"},{"issue":"10","key":"1514_CR20","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen\u00a0A, M\u00fcller\u00a0F, Mougiakakos\u00a0D, B\u00f6ltz\u00a0S (2022) Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"issue":"10379","key":"1514_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller\u00a0F, Boeltz\u00a0S, Knitza\u00a0J, Aigner\u00a0M, V\u00f6lkl\u00a0S, Kharboutli\u00a0S et\u00a0al (2023) CD19-targeted CAR T\u00a0cells in refractory antisynthetase syndrome. Lancet 401(10379):815\u2013818","journal-title":"Lancet"},{"issue":"24","key":"1514_CR22","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher\u00a0AC, Hensen\u00a0L, Klein\u00a0R, Schairer\u00a0R, Lutz\u00a0K, Atar\u00a0D et\u00a0al (2023) CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. JAMA 329(24):2154\u20132162","journal-title":"JAMA"},{"issue":"8","key":"1514_CR23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann\u00a0C, M\u00fcller\u00a0F, Distler\u00a0JHW et\u00a0al (2023) Treatment of a\u00a0patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T\u00a0cells. Ann Rheum Dis 82(8):1117\u20131120. https:\/\/doi.org\/10.1136\/ard-2023-223952","journal-title":"Ann Rheum Dis"},{"key":"1514_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt\u00a0W, Freitag\u00a0M, Claus\u00a0M (2024) et\u00a0al. Third-generation CD19.CAR-T\u00a0cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 83:543\u2013546","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1514_CR25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L et\u00a0al (2024) CD19 CAR T\u2011Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up. N Engl J Med 390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"issue":"11","key":"1514_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers12113445","volume":"12","author":"O Penack","year":"2020","unstructured":"Penack\u00a0O, Koenecke\u00a0C (2020) Complications after CD19+ CAR T\u2011Cell Therapy. Cancers 12(11):19","journal-title":"Cancers"},{"issue":"26","key":"1514_CR27","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno\u00a0JN, Kochenderfer\u00a0JN (2016) Toxicities of chimeric antigen receptor T\u00a0cells: recognition and management. Blood 127(26):3321\u20133330","journal-title":"Blood"},{"issue":"1","key":"1514_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","volume":"2016","author":"NV Frey","year":"2016","unstructured":"Frey\u00a0NV, Porter\u00a0DL (2016) Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2016(1):567\u2013572","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1514_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719899897","author":"T Jain","year":"2020","unstructured":"Jain T, Litzow MR (2020) Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Ther Adv Hematol. https:\/\/doi.org\/10.1177\/2040620719899897","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"1514_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth\u00a0VS, Gauthier\u00a0J (2021) Taming the beast: CRS and ICANS after CAR T\u2011cell therapy for ALL. Bone Marrow Transplant 56(3):552\u2013566","journal-title":"Bone Marrow Transplant"},{"key":"1514_CR31","unstructured":"Taubmann J, M\u00fcller F, Aigner M, Minopoulou I, Knitza J, Werner D, Bergmann C, Kroenke G, Mackensen A, Schett G (2023) Tolerability of CAR T\u00a0Cell Therapy in Autoimmune Disease.\n\t    Arthritis Rheumatol 75(suppl 9). https:\/\/acrabstracts.org\/abstract\/tolerability-of-car-t-cell-therapy-in-autoimmune-disease\/. Zugegriffen: 7. Mai 2024"},{"key":"1514_CR32","unstructured":"(2023) US FDA. FDA Investigating Serious Risk of T\u2011cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T\u00a0cell Immunotherapies. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous"},{"key":"1514_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN et\u00a0al (2024) T\u00a0cell lymphoma and secondary primary malignancy risk after commercial CAR T\u00a0cell therapy. Nat Med 30:984\u2013989","journal-title":"Nat Med"},{"key":"1514_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie\u00a0RA, Aroca\u00a0G, Cascino\u00a0MD et\u00a0al (2022) B\u2011cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a\u00a0randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100\u2013107","journal-title":"Ann Rheum Dis"},{"key":"1514_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee\u00a0DSW, Rojas\u00a0OL, Gommerman\u00a0JL (2021) B\u00a0cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 20:179\u2013199","journal-title":"Nat Rev Drug Discov"},{"key":"1514_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418761697","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, St\u00fcve O (2018) B\u00a0cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/1756286418761697","journal-title":"Ther Adv Neurol Disord"},{"key":"1514_CR37","doi-asserted-by":"publisher","unstructured":"Bucci\u00a0L, Hagen\u00a0M, Rothe\u00a0T, et al. (2024) Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-02964-1, published online April 26","DOI":"10.1038\/s41591-024-02964-1"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01514-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:05:32Z","timestamp":1723561532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01514-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01514-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"15 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Hagen, A.\u00a0Wirsching, D.\u00a0Bohr, J.\u00a0Taubmann, F.\u00a0M\u00fcller, A.\u00a0Mackensen, R.\u00a0Grieshaber-Bouyer und G.\u00a0Schett geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}